| NCT07209462 | Study of MRM-3379 in Male Participants With Fragile X Syndrome | RECRUITING | PHASE2 | 2025-12 | 2027-10 | 2027-10 |
| NCT06553768 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | RECRUITING | PHASE3 | 2024-10-14 | 2027-02 | 2026-10 |
| NCT05050136 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | RECRUITING | PHASE2 | 2021-09-22 | 2027-07 | 2027-04 |
| NCT04729751 | A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). | COMPLETED | PHASE2 | 2021-09-09 | 2024-12-17 | 2024-12-17 |
| NCT04524390 | Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai | COMPLETED | PHASE2 | 2021-07-08 | 2024-02-07 | 2023-11-07 |
| NCT04718961 | A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) | TERMINATED | PHASE2 | 2021-01-04 | 2022-12-07 | 2022-12-07 |
| NCT04663308 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-12-18 | 2027-04 | 2026-06 |
| NCT04270682 | Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) | COMPLETED | PHASE3 | 2020-01-31 | 2023-10-04 | 2023-07-13 |
| NCT04168385 | MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study | COMPLETED | PHASE2 | 2020-01-16 | 2024-09-04 | 2024-09-04 |
| NCT04185363 | An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) | COMPLETED | PHASE3 | 2020-01-08 | 2025-04-23 | 2025-04-23 |
| NCT03905330 | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) | COMPLETED | PHASE3 | 2019-07-09 | 2022-09-01 | 2022-09-01 |
| NCT03353454 | A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) | WITHDRAWN | PHASE3 | 2018-10-25 | 2020-06-15 | 2020-06-15 |
| NCT02787304 | Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) | TERMINATED | PHASE2 | 2016-10-24 | 2018-07-27 | 2018-07-27 |
| NCT02571192 | A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose | COMPLETED | PHASE1 | 2015-10-01 | 2015-10-01 | 2015-10-01 |
| NCT02475317 | Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion | COMPLETED | PHASE1 | 2015-06-01 | 2015-12-01 | 2015-12-01 |
| NCT02321306 | An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis | WITHDRAWN | PHASE2 | 2015-05 | 2018-03 | 2017-12 |
| NCT02117713 | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome | COMPLETED | PHASE2 | 2015-03-16 | 2020-06-01 | 2020-06-01 |
| NCT02287779 | Safety and Tolerability Study of SHP626 in Overweight and Obese Adults | COMPLETED | PHASE1 | 2015-01-19 | 2015-06-19 | 2015-06-19 |
| NCT02057692 | Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome | COMPLETED | PHASE2 | 2014-11-24 | 2016-11-16 | 2016-11-16 |
| NCT02160782 | Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) | COMPLETED | PHASE2 | 2014-10-28 | 2020-05-28 | 2020-05-28 |
| NCT02057718 | Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis | COMPLETED | PHASE2 | 2014-03-01 | 2020-05-08 | 2020-05-08 |
| NCT02061540 | Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis | COMPLETED | PHASE2 | 2014-03 | 2016-02 | 2016-02 |
| NCT02047318 | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) | COMPLETED | PHASE2 | 2013-12-20 | 2020-06-17 | 2020-06-17 |
| NCT01903460 | Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome | COMPLETED | PHASE2 | 2013-08 | 2015-03 | 2015-02 |
| NCT01904058 | Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis | COMPLETED | PHASE2 | 2013-08 | 2015-04 | 2015-04 |
| NCT01115582 | Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis | COMPLETED | PHASE3 | 2010-04 | 2010-08 | 2010-08 |
| NCT01438411 | Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis | COMPLETED | PHASE3 | 2010-01 | 2016-07 | 2016-07 |
| NCT00007020 | Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid | COMPLETED | PHASE3 | 1992-01 | 2009-12 | 2009-12 |